Funding Opportunities
Now Accepting Applications
Sylvester Braman Family Breast Cancer Institute’s Women’s Cancer League Developmental Grant Competition 2012-13
This program provides funds to encourage the development of new research directed toward basic, translational and clinical research in breast and ovarian cancers. The support of pilot projects is intended, ultimately, to foster initiation of research to move findings in a scientific field toward novel clinical implementation and provocative clinical observations back to the laboratory. A goal of this funding mechanism is that research projects will ultimately grow into full R01 proposals. Support from the State of Florida and the Women’s Cancer League allows the BFBCI to fund projects of relevance to breast and ovarian cancer in this round of grant funding. An applicant whose project was funded in the previous grant cycle is not eligible for funding of a new project in the following year. Individuals must have independent research and laboratory space to be eligible. Only Cancer Center Members may apply. Three awards of $50,000 each are available with a one-year project period from July 1, 2012 to June 30, 2013.
Deadline extended: June 1, 2012
For application and more information, please contact Tracy Wieder by phone at 305-243-7262, email at twieder@med.miami.edu, or in person at Fox Building, Suite 430A.
American Cancer Society Institutional Research Grant (ACS IRG) Pilot Projects Grant
This program provides funds for meritorious cancer research that cannot be readily supported through other funding mechanisms. The primary purpose of the ACS IRG Pilot Projects Grant is to provide seed funds for the initiation of promising new projects or novel ideas by junior faculty members. Applicants should have less than six years experience in an independent research or faculty appointment and must not currently hold any peer-reviewed funding. Senior faculty and postdoctoral fellows are not eligible to apply. Three awards of $45,000 each are available with a one-year project period from June 1, 2012 to May 31, 2013.
Deadline: March 1, 2012
For application and more information, please contact Tracy Wieder by phone at 305-243-7262, email at twieder@med.miami.edu, or in person at Fox Building, Suite 430A.
Awardees
Braman Family Breast Cancer Institute Women’s Cancer League Developmental Grant Program
Sylvester Comprehensive Cancer Center is pleased to announce the most recent Braman Family Breast Cancer Institute Women’s Cancer League Developmental Grant Program awardees.
These developmental grants are intended to encourage and support promising new basic, translational and clinical research in breast and ovarian cancer. The support of pilot projects is intended to foster initiation of research to move findings in a scientific field toward novel clinical implementation and provocative clinical observations back to the laboratory.
Congratulations to the 2011 awardees:
- Karoline Briegel, Ph.D., Department of Biochemistry and Molecular Biology, for “Role of T-box Transcription Factor TBX2 in Breast Cancer Metastasis”
- Dorraya El-Ashry, Ph.D., Department of Medicine, Division of Hematology/Oncology, for “MAPK Regulated miRNAs in the Regulation of ERα and p27kip1 in ER-Negative Breast Cancer”
- Xin-Hai Pei, MD, Ph.D., Department of Surgery, for “Function of BRCA1 in Maintaining Mammary Luminal Cell Fate and Suppressing Epithelial to Mesenchymal Transition and Tumorigenesis”
We thank all investigators who participated in the process.
American Cancer Society Institutional Research Grant
Sylvester Comprehensive Cancer Center is pleased to announce the most recent American Cancer Society Institutional Research Grant awardees.
The American Cancer Society Institutional Research Grant provides funds for meritorious cancer research that cannot be readily supported through other funding mechanisms. The primary purpose of the ACS IRG grant is to provide seed funds for the initiation of promising new projects or novel ideas by junior faculty members.
Congratulations to the 2011 awardees:
- Juan Diez, Ph.D., Department of Surgery, for “Characterization of NACK, a New Co-Activator of Notch”
- Gregory Holt, MD, Ph.D., Department of Medicine, for “Evaluation of a Novel Reagent to Specifically Deliver Plasmid DNA to Non Small Cell Lung Cancer”
- Geoffrey Stone, Ph.D., Department of Microbiology & Immunology, for “In vivo Targeting of Dendritic Cells with Tumor Antigens Using a Novel Cancer Therapy”
Special thanks to all the applicants and reviewers that participated during the award process.
Sylvester Investigator Initiated Trials (SIIT) Grant
Sylvester Comprehensive Cancer Center is pleased to announce the first recipients of the Sylvester Investigator Initiated Trials (SIIT) Grant.
A major goal of Sylvester is to support the development of cancer-focused investigator initiated trials. These types of trials continue to be a high priority regarding clinical research and historically have been proven to be underfunded. In order to maintain the continuity of our investigator initiated trials, funds will be provided to sustain trials that are competitive for external funding.
The purpose of this mechanism is to provide bridge funds to support investigator initiated trials, until such time that the PI will receive grants from other sources. Each award covers the start up costs for the trial plus patient care costs of 30% of proposed patients up to $30,000.
Congratulations to the 2011 cycle one awardees:
- Gustavo Fernandez, M.D., from the Department of Medicine, Division of Hematology/Oncology, for “Targeted Therapy to Receptors for LH-RH in Urothelial Carcinoma”
- Jean Wright, M.D., from the Department of Radiation Oncology for “A Phase I Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients with Bulky Stage III Non-Small Cell Lung Cancer”
Congratulations to the 2011 cycle 2/3 awardees:
- Pereira, Denise, M.D., from the Department of Medicine, for “Pilot Study to Evaluate Fenofibrate Therapy in Relapsed or Refractory Multiple Myeloma (MM) After At Least Two Prior Lines of Therapy”
- Montero, Alberto, M.D., from the Department of Medicine, for “A Randomized, Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative (ER/PR/Her-2 Negative) LHRH-R Positive Metastatic Breast Cancer”
Funding Newsletter
The monthly Funding Newsletter compiles information on local and national awards/grants for doctors and researchers. Included are NIH notices, foundation and other sources, program announcements, and requests for applications.